10:45 AM EST - NeurAxis, Inc. : Today highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS™) in Patients with Post-Concussion Syndrome (PCS) , a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim™ in children with post-concussion symptoms. Currently enrolling up to 100 patients, the clinical trial’s primary endpoint is improvements in validated measures, including the Immediate Post-Concussion Assessment, Post-Concussion Symptom Scale, and Balance Error Scoring Symptom compared to placebo. The trial is being conducted at Children’s Hospital of Orange County, CA. NeurAxis, Inc.
shares NY.NRXS are trading off 1 cent at $4.70.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=NRXS&qmodStoryID=6232111518883214
